Atteintes ophtalmologiques des traitements systémiques (hors neuropathies optiques) DOI
Audrey Rousseau, R. C. Boucher,

M. Labetoulle

et al.

Encyclopédie médico-chirurgicale. Ophtalmologie, Journal Year: 2024, Volume and Issue: 41(3), P. 1 - 15

Published: Sept. 1, 2024

Diagnosing and Managing Uveitis Associated with Immune Checkpoint Inhibitors: A Review DOI Creative Commons
Huixin Zhang,

Lysa Houadj,

Kevin Y. Wu

et al.

Diagnostics, Journal Year: 2024, Volume and Issue: 14(3), P. 336 - 336

Published: Feb. 4, 2024

This review aims to provide an understanding of the diagnostic and therapeutic challenges uveitis associated with immune checkpoint inhibitors (ICI). In wake these molecules being increasingly employed as a treatment against different cancers, cases post-ICI therapy have also been reported in literature, warranting extensive exploration clinical presentations, risk factors, pathophysiological mechanisms ICI-induced uveitis. further provides association between ICIs uveitis, assesses efficacy current tools, underscoring need for advanced techniques enable early detection accurate assessment. Further, it investigates strategies ICI-related weighing benefits limitations existing regimens, discussing emerging therapies context their potential side effects. Through overview short-term long-term outcomes, this article suggests recommendations emphasizes importance multidisciplinary collaboration ophthalmologists oncologists. Finally, highlights promising avenues future research development field, potentially informing transformative approaches ocular assessment patients under immunotherapy management following ICI therapy.

Language: Английский

Citations

9
Pathogenic mechanisms of immune checkpoint inhibitor (ICI)-associated retinal and choroidal adverse reactions DOI
Rachana Haliyur, Victor M. Elner, Thérèse M. Sassalos

et al.

American Journal of Ophthalmology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

1
Mechanisms of blood-retinal barrier disruption related to intraocular inflammation and malignancy DOI Creative Commons
Oren Tomkins‐Netzer, Rachael L. Niederer, John Greenwood

et al.

Progress in Retinal and Eye Research, Journal Year: 2024, Volume and Issue: 99, P. 101245 - 101245

Published: Jan. 21, 2024

Blood-retinal barrier (BRB) disruption is a common accompaniment of intermediate, posterior and panuveitis causing leakage into the retina macular oedema resulting in vision loss. It much less anterior uveitis or patients with intraocular lymphoma who may have marked signs inflammation. New drugs used for chemotherapy (cytarabine, immune checkpoint inhibitors, BRAF EGFR bispecific anti-EGFR MET receptor inhibitors Bruton tyrosine kinase inhibitors) can also cause different types BRB disruption. As malignant disease itself uveitis, particularly from breast, lung gastrointestinal tract cancers, it be clinically difficult to sort out Immunosuppression due and/or lead infection which infection. In this paper we address pathophysiology related inflammation malignancy, methods estimating extent effect examine why some malignancy others do not. Understanding help manage these patients, as well devise future therapeutic approaches.

Language: Английский

Citations

6
Immune checkpoints: new insights into the pathogenesis of thyroid eye disease DOI Creative Commons

Xingyi Shu,

Yuchao Shao, Yuqing Chen

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: May 16, 2024

Thyroid eye disease (TED) is a disfiguring autoimmune characterized by changes in the orbital tissues and caused abnormal thyroid function or thyroid-related antibodies. It ocular manifestation of Graves' disease. The expression thyroid-stimulating hormone receptor (TSHR) insulin-like growth factor-1 (IGF-1 R) on cell membrane fibroblasts (OFs) responsible for TED pathology. Excessive inflammation when these receptors orbit are stimulated autoantibodies. CD34

Language: Английский

Citations

6
Real-World Evidence for Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Scoping Review DOI Creative Commons
Varun Chaudhary, Robyn H. Guymer,

Audrey Artignan

et al.

Ophthalmology Science, Journal Year: 2025, Volume and Issue: 5(4), P. 100744 - 100744

Published: Feb. 22, 2025

Language: Английский

Citations

0
Case of uveitis with increased electroretinographic amplitudes following Nivolumab and Ipilimumab administration for malignant melanoma DOI
Kumiko Kato,

Ryunosuke Nagashima,

Hisashi Matsubara

et al.

Documenta Ophthalmologica, Journal Year: 2025, Volume and Issue: unknown

Published: March 12, 2025

Language: Английский

Citations

0
Clinical and imaging strategies for the assessment of the ocular side effects of systemic targeted anti-cancer therapies DOI Creative Commons
L. Michaels, Maha Noor, Tariq Aslam

et al.

European Journal of Cancer, Journal Year: 2025, Volume and Issue: unknown, P. 115452 - 115452

Published: April 1, 2025

Systemic targeted anti-cancer therapies selectively target cancerous cells whilst limiting systemic side effects. The eye however, is a particularly sensitive organ and the expanding use of newer chemotherapy agents has been associated with multiple ocular In this review we provide an update effects along suggested minimum, pragmatic, evidence-based strategies for effective screening or monitoring potential This framework designed to guide oncologists, trial managers, protocol developers regulatory authorities so that appropriate ophthalmic clinical examinations non-invasive modern imaging can be requested commissioned according patient's specific treatment.

Language: Английский

Citations

0
Impact of immune checkpoint inhibitors on vision and eye health DOI Creative Commons

Mouayad Masalkhi,

Noura Wahoud, Bridget Moran

et al.

Eye, Journal Year: 2024, Volume and Issue: 38(15), P. 2854 - 2856

Published: July 3, 2024

Language: Английский

Citations

3
Cytokines in PD-1 immune checkpoint inhibitor adverse events and implications for the treatment of uveitis DOI Creative Commons
Aaron C. Brown, José Quiroz, Devayu Parikh

et al.

BMC Ophthalmology, Journal Year: 2024, Volume and Issue: 24(1)

Published: July 29, 2024

Abstract Immune checkpoint inhibitors (ICI) such as Programmed cell Death 1 (PD-1) have improved cancer treatment by enhancing the immune system’s ability to target malignant cells. Their use is associated with immune-related adverse events (irAEs), including uveitis. The profile of pro-inflammatory cytokines underlying Anti-PD-1-induced uveitis shares significant overlap that non-infectious Current corticosteroid treatments for while effective are fraught vision threatening side effects. cytokine in ICI-related has a large noninfectious uveitis, this strongly supports potential therapy activates PD-1 axis eye treat Indeed, ICI related often resolves cessation ICI, restoring endogenous axis. benefit targeting many via local activation mitigating ocular inflammation minimizing

Language: Английский

Citations

3
Bilateral Vitiligo-Like Depigmentation of Choroid and Retinal Pigment Epithelium Associated with Ipilimumab-Nivolumab Therapy for Metastatic Cutaneous Melanoma DOI Creative Commons

Caroline C. Cotton,

Anirudha S. Chandrabhatla,

Mackenzie L. Higgins

et al.

Case Reports in Oncology, Journal Year: 2024, Volume and Issue: 17(1), P. 122 - 127

Published: Jan. 23, 2024

<b><i>Introduction:</i></b> Ipilimumab and nivolumab are checkpoint inhibitors that known to cause a multitude of inflammatory ocular adverse events. Here we report patient with poliosis symptomatic depigmentation the choroid retinal pigment epithelium (RPE) associated inhibitor therapy for cutaneous melanoma. <b><i>Case Presentation:</i></b> The presented floaters in both eyes concerns intraocular metastases metastatic melanoma after 1 month ipilimumab nivolumab. External examination revealed her eyebrows eyelashes. Fundus photography demonstrated multiple 1–3 disc-diameter hypopigmented placoid flat areas RPE/choroid exposing underlying choroidal vessels eyes. At subsequent evaluation 7 months later (after an additional 6 therapy), lesions appeared more blanched. Evaluation nearly 20 initial presentation showed no significant changes from prior visit despite cessation 13 months. <b><i>Conclusion:</i></b> Checkpoint can RPE must be differentiated progression

Language: Английский

Citations

2